| Property | Value |
|---|
|
?:abstract
|
-
More than 15 million people have been affected by coronavirus disease 2019 (COVID‐19) and it has caused 640016 deaths as of July 26, 2020. Currently, no effective treatment option is available for COVID‐19 patients. Though many drugs have been proposed, none of them has shown particular efficacy in clinical trials. In this article, I focus on the relationship between the Adrenergic system and the renin‐angiotensin‐aldosterone system (RAAS) in COVID‐19 and propose a vicious circle consisting of the Adrenergic system‐RAAS‐Angiotensin converting enzyme 2 (ACE2)‐SARS‐CoV‐2 (which I refer to as the “ARAS loop”). Hyperactivation of the ARAS loop may be the underlying pathophysiological mechanism in COVID‐19, and I propose beta‐adrenergic blockers as a potential treatment option. Beta‐adrenergic blockers may decrease the SARS‐CoV‐2 cellular entry by decreasing ACE2 receptors expression and CD147 in various cells in the body. Beta‐adrenergic blockers may decrease the morbidity and mortality in COVID‐19 patients by preventing or reducing acute respiratory distress syndrome (ARDS) and other complications. Retrospective and prospective clinical trials should be conducted to check the validity of the hypothesis. This article is protected by copyright. All rights reserved
|
|
?:creator
|
|
|
?:doi
|
|
|
?:doi
|
|
|
?:journal
|
|
|
?:license
|
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/7b9dc75583e9d752e9927e25a279dc60f05279e0.json
|
|
?:pmcid
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:sha_id
|
|
|
?:source
|
|
|
?:title
|
-
Beta‐adrenergic Blockers as a Potential Treatment for COVID‐19 Patients
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}